Real-World Practice Patterns and Outcomes of Lower-Risk Myelodysplastic Syndrome Patients in Japan
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
177actual
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-22 | actual | When the study began enrolling |
| Primary completion | 2025-07-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-09 | actual | The whole study's end, after follow-up |
| First posted | 2024-03-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lower-risk Myelodysplastic Syndromes
Interventions
- Procedure: Red blood cell transfusion
- Procedure: Red blood cell transfusion
Primary outcomes
what the primary-completion date above is the date OFParticipant age
measured At date of diagnosis
Participant sex
measured At date of diagnosis
Participant weight
measured At date of diagnosis
Participant height
measured At date of diagnosis
Participant comorbidities calculated using the Charlson Comorbidity Index (CCI) method
measured From 30 days prior to diagnosis up to 7 days post to diagnosis
Participant Eastern Cooperative Oncology Group (ECOG) score
measured From 30 days prior to diagnosis up to 7 days post to diagnosis
Participant International Prognostic Scoring System (IPSS) or Revised International Prognostic Scoring System (IPSS-R) risk category
measured Date of diagnosis, 6-months and 12 months post-diagnosis
Percentage of ring sideroblasts present in participants
measured Date of bone marrow test; from 30 days prior to diagnosis up to 7 days post to diagnosis
Percentage of bone marrow blasts present in participants
measured From 30 days prior to diagnosis up to 7 days post to diagnosis
Histopathology results
measured From 30 days prior to diagnosis up to 7 days post to diagnosis
Number of red-blood cell transfusions received by participants
measured Up to 56 days post diagnosis
Treatment prescribed by line of therapy
measured From date of diagnosis, up to 5-years
Duration of treatment by line of therapy
measured From date of diagnosis, up to 5-years
Time between date of diagnosis and treatment
measured From date of diagnosis to treatment initiation
Time between date of treatment initiation to treatment discontinuation
measured Date of treatment initiation, up to 5-years
Time between date of diagnosis to date of first red-blood cell transfusion
measured Date of diagnosis, up to 5-years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed